A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer

BACKGROUND: Gefitinib is an oral EGFR tyrosine kinase inhibitors which may act as a radiosensitizer. PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Levy, Antonin, Bardet, Etienne, Lacas, Benjamin, Pignon, Jean-Pierre, Adam, Julien, Lacroix, Ludovic, Artignan, Xavier, Verrelle, Pierre, Le Péoux, Cécile
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5362534/
https://ncbi.nlm.nih.gov/pubmed/27764781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12741
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars